Theramedix Retatrutide (pronounced Ret-uh-true-tide) is a premium-grade synthetic next-generation investigational peptide designed to treat obesity and type 2 diabetes. This next-generation peptide agent acts as a triple hormone receptor agonist, simultaneously targeting:

• GLP-1 (Glucagon-like peptide-1)
• GIP (Glucose-dependent insulinotropic polypeptide)
• Glucagon receptors

By activating all three, Retatrutide addresses multiple metabolic pathways: appetite regulation, insulin secretion, energy expenditure, and fat metabolism, offering a more powerful therapeutic response than single or dual agonists like Semaglutide or Tirzepatide.

This product is intended exclusively for laboratory investigation, analytical study, and in-vitro use and is not for human or clinical use.